MOUNTAIN VIEW, Calif., Sept. 20, 2012 /PRNewswire/ -- VIVUS, Inc. (Nasdaq:VVUS) today announced that multiple scientific abstracts will be presented at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society, to be held September 20 th to September 24 th in San Antonio, Texas. The Obesity Society's Annual Scientific Meeting has grown to be one of the largest gatherings of obesity professionals worldwide.
The posters will be displayed in Exhibit Hall C of the Henry B. Gonzalez Convention Center in San Antonio from Thursday, September 20 th until Saturday, September 22 nd. Presenters will be at their posters on September 22, 2012 from 12:00 p.m. to 1:30 p.m. CDT.
Title: Weight Loss and Reduction in Unique Antidiabetic Medication Use in Obese Subjects With Type 2 Diabetes Mellitus Using Extended-Release Phentermine/Topiramate Over 2 YearsLead Authors: T. GarveyPoster Number: 459-P
Title: Weight Loss by Degree of Comorbidity as Assessed by the Edmonton Obesity Staging System in Subjects Receiving Extended-Release Phentermine/TopiramateLead Author: L. J. CheskinPoster Number: 460-P
Title: Weight Loss and Changes in Blood Pressure and Triglycerides by Degree of Comorbidity in Subjects Receiving Extended-Release Phentermine/Topiramate Lead Author: A. M. SharmaPoster Number: 461-P
Title: Reduction in Cardiovascular Risk Associated With Weight Loss in Three Clinical Trials of Obese Subjects Receiving Extended-Release Phentermine/TopiramateLead Author: T. Church Poster Number: 462-P
Title: Application of Proposed Treatment Algorithm Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release TopiramateLead Authors: R. DvorakPoster Number: 34-LB-P
Qsymia™ (pronounced Kyoo sim ee' uh) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.Important Safety Information Qsymia (phentermine and topiramate extended-release) capsules CIV must not be used by women who are pregnant; by patients with eye problems (glaucoma); by patients who have been told they have an overactive thyroid; by patients taking a type of anti-depressant called MAOI; or by patients who are allergic to phentermine, topiramate, or any of the ingredients in Qsymia. Qsymia can harm your unborn baby. If you take Qsymia while you are pregnant, your baby has a higher risk for birth defects called cleft lip and cleft palate. You should have a negative pregnancy test before taking Qsymia and every month while taking Qsymia. Use effective birth control (contraception) consistently while taking Qsymia. If you become pregnant while taking Qsymia, you should stop taking Qsymia immediately and contact your healthcare provider right away.